ASCENSIA DIABETES CARE EXPANDS PAYMENT ASSISTANCE AND SIMPLE SAVINGS PROGRAM FOR EVERSENSE E3 CGM System
Parsippany, United States
Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, announces that it has significantly expanded Eversense PASS, a Payment Assistance and Simple Savings program designed to enhance affordability and access to the Eversense E3 CGM System. Under the new and improved program, more people with diabetes will be eligible for assistance paying for the system, which now includes increased savings for eligible first time users.
Created by Ascensia, the Eversense PASS program has been helping eligible patients in the U.S. access Eversense E3 and its benefits since April 2022. Eligibility for the program has now been extended to all commercially insured people with diabetes across the country, including those who do not have coverage for the Eversense E3 system from their insurance provider. Additionally, new Eversense E3 users will now only pay $99 out of pocket for their first two Eversense E3 systems* extending the $99 introductory offer that was previously available for just the initial sensor and smart transmitter. This results in an out-of-pocket cost of less than $200 for an entire year of continuous glucose monitoring with Eversense E3 for new users†. For each sensor thereafter, users will pay a maximum of $100 per month, or $600 for the six-month duration of each sensor.
“We’ve been working to ensure that as many people as possible can have access to this unique product,” said Rudy Thoms, VP, CGM Commercial US of Ascensia Diabetes Care. “Alongside our partner Senseonics, we know the positive impact that Eversense E3 can have on the lives of people with diabetes and that’s one of many reasons why we are pleased to extend the savings and eligibility for Eversense PASS. Although most major insurers now cover Eversense E3 CGM System, we are also proud to offer these savings regardless of coverage, so that no one with commercial insurance is left behind.”
Designed by Senseonics (NYSE: SENS) and brought to patients by Ascensia, the Eversense E3 CGM System offers people with diabetes:
- The longest lasting CGM available, with up to 6-month sensor wear duration and approximately two sensor insertion and removal procedures per year
- Exceptional accuracy, with a mean absolute relative difference (MARD) of 8.5%‡ demonstrated in the PROMISE Study for the duration of sensor wear
- A fully implantable fluorescence-based sensor, with a removable smart transmitter§ that provides discreet on-body vibe alerts and transmits data to a mobile app
- Fewer calibrations, with primarily one calibration required per day after day 21 of use
Potential Eversense E3 users can go to www.ascensiadiabetes.com/eversense to learn more about the program and find out if they are eligible. Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense E3 CGM System can sign up at https://www.ascensiadiabetes.com/eversense/become-a-provider/. Alternatively, contact 1-844-SENSE4U (1-844-736-7348) to learn more about the first and only long-term implantable CGM system.
Ascensia Diabetes Care is a PHC Holdings Corporation (TSE: 6523) company.
*This excludes cost for insertion procedure
†Based on a sensor life of 6 months
‡MARD of 9.1% was observed in primary sensor in the PROMISE Study
§ There is no glucose data generated when the transmitter is removed
1Garg S. et al. Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technology & Therapeutics 2021; 24(2): 1-9.DOI: 10.1089/dia.2021.0182
Notes for Editors
About Ascensia Diabetes Care
Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives.
We are home to the world-renowned CONTOUR® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.
Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 125 countries. Ascensia has around 1,500 employees and operations in 31 countries.
For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com
About PHC Holdings Corporation
PHC Holdings Corporation (TSE 6523), or PHC Group, is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia, and LSI Medience Corporation. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s consolidated net sales in FY2021 were JPY 340 billion with global distribution of products and services in more than 125 countries. www.phchd.com
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see https://www.ascensiadiabetes.com/eversense/safety-info/.
For more media enquiries, please contact:
Tim Stamper, Tim.Stamper@FTIConsulting.com